Dr. Teresita Rodríguez Obaya, biotechnology scientist and founder of Cuba’s Centre of Molecular Immunology (CIM), developed NeuroEPO (brand name NeuralCIM) to treat Parkinson’s, strokes, and ataxia. In more recent research on the drug, Dr. Obaya and colleagues have found that it significantly delays, and sometimes halts, Alzheimer’s progress. This new drug is undergoing the third phase of a 3-part study of efficacy, which is documented by Belly of the Beast under the title Teresita’s Dream: Cuba’s Battle Against Alzheimer’s. The results are promising, especially for anybody who has witness the decline of a loved one due to the disease.
Because of the decades-long U.S. blockade, making NeuroEPO has not been easy. Like many of the things needed for health and wellbeing, the supplies Cuban biotechnology scientists need for their research is widely limited. The U.S. blockade prevents any items made with more than 10% U.S. material from reaching Cuba, basically cutting Cuba off from most nearby and even far away resources. Further, the U.S. blockade prevents people in the U.S. from supporting science and research, like that reported here, that has the potential of benefiting so many lives.
Cuba SÍ Colorado 